Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Tislelizumab × Gastrointestinal × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3538 Pancreatic Neoplasms 2214 Carcinoma, Hepatocellular 2141 Stomach Neoplasms 1880 Rectal Neoplasms 1486 Colonic Neoplasms 1440 Esophageal Neoplasms 1169 Liver Neoplasms 774 Neoplasms 566 Breast Neoplasms 526 Cholangiocarcinoma 456 Gastrointestinal Neoplasms 418 Neoplasm Metastasis 392 Esophageal Squamous Cell Carcinoma 390 Lung Neoplasms 365 Prostatic Neoplasms 245 Biliary Tract Neoplasms 241 Ovarian Neoplasms 209 Barrett Esophagus 206 Adenocarcinoma Of Esophagus 180 Gallbladder Neoplasms 173 Gastrointestinal Stromal Tumors 163 Anus Neoplasms 161 Carcinoma, Non-Small-Cell Lung 160 Head and Neck Neoplasms 159 Recurrence 154 Adenocarcinoma 142 Melanoma 141 Bile Duct Neoplasms 134 Uterine Cervical Neoplasms 131

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡